Literature DB >> 16410024

Lipid metabolism in cognitive decline and dementia.

Francesco Panza1, Alessia D'Introno, Anna Maria Colacicco, Cristiano Capurso, Gianfranco Pichichero, Sabrina A Capurso, Antonio Capurso, Vincenzo Solfrizzi.   

Abstract

This review will focus on the current knowledge on circulating serum and plasma risk factors of cognitive decline of degenerative (Alzheimer's disease, AD) or vascular origin (vascular dementia, VaD) linked to cholesterol homeostasis and lipoprotein disturbances, i.e. total cholesterol (TC), 24S-hydroxy-cholesterol, lipoprotein(a) (Lp(a)), or apolipoprotein E (APOE). These measures linked to lipoprotein metabolism appear to be altered in AD, VaD, or predementia syndrome relative to controls, but with contrasting results. At present, several studies have demonstrated the dependence of APOE serum levels upon the APOE genotype, nonetheless serum APOE levels seems not to be a credible risk factor or a biochemical marker for AD instead of APOE genotyping. In fact, there was no consistent association of serum or plasma apoE protein levels with the disease when controlled for APOE genotype. In addition, there are some evidence that higher Lp(a) levels could be linked with AD, although there are studies suggesting an increased presence of low molecular weight apo(a) in AD, VaD, and frontotemporal dementia, that are associated with elevated Lp(a) levels. In fact, the apo(a) gene is highly polymorphic in length due to variation in the numbers of a sequence encoding the apo(a) kringle 4 domain, and plasma levels of Lp(a) are inversely correlated with apo(a) size. Furthermore, although serum/plasma levels of TC and 24S-hydroxycholesterol are not credible diagnostic markers for AD and cognitive decline, the current evidence suggests that they may be modifiable risk/protective factors. The prevailing wisdom is that high TC is a risk factor for dementia. However, the relationship between TC and dementia may vary considerably depending on when cholesterol is measured over the life course or, alternatively, in relation to the underlying course of the disease. Several observational studies have suggested that statins, which are effective in lowering cholesterol, may reduce the risk of dementia, but the results of these reports are inconclusive. Thus, more studies with long-term follow-up and serial assessments of TC are needed to further clarify the causal relationship between cholesterol and dementia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16410024     DOI: 10.1016/j.brainresrev.2005.11.007

Source DB:  PubMed          Journal:  Brain Res Rev        ISSN: 0165-0173


  49 in total

Review 1.  Growing old with epilepsy: the neglected issue of cognitive and brain health in aging and elder persons with chronic epilepsy.

Authors:  Bruce Hermann; Michael Seidenberg; Mark Sager; Cynthia Carlsson; Barry Gidal; Raj Sheth; Paul Rutecki; Sanjay Asthana
Journal:  Epilepsia       Date:  2007-11-21       Impact factor: 5.864

Review 2.  The effects of cholesterol on learning and memory.

Authors:  Bernard G Schreurs
Journal:  Neurosci Biobehav Rev       Date:  2010-05-12       Impact factor: 8.989

3.  Classification models for early identification of persons at risk for dementia in primary care: an evaluation in a sample aged 80 years and older.

Authors:  Tessa N van den Kommer; Daniel E Bontempo; Hannie C Comijs; Scott M Hofer; Miranda G Dik; Andrea M Piccinin; Cees Jonker; Dorly J H Deeg; Boo Johansson
Journal:  Dement Geriatr Cogn Disord       Date:  2009       Impact factor: 2.959

Review 4.  Role of HMG-CoA reductase inhibitors in neurological disorders : progress to date.

Authors:  Allison B Reiss; Elzbieta Wirkowski
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 5.  Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.

Authors:  Carmen Noelker; Harald Hampel; Richard Dodel
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

6.  Neuropsychological Functioning in Mid-life Treatment-Seeking Adults with Obesity: a Cross-sectional Study.

Authors:  Christina Prickett; Renerus Stolwyk; Paul O'Brien; Leah Brennan
Journal:  Obes Surg       Date:  2018-02       Impact factor: 4.129

7.  Predictors of neurodegeneration differ between cognitively normal and subsequently impaired older adults.

Authors:  Nicole M Armstrong; Yang An; Lori Beason-Held; Jimit Doshi; Guray Erus; Luigi Ferrucci; Christos Davatzikos; Susan M Resnick
Journal:  Neurobiol Aging       Date:  2018-11-02       Impact factor: 4.673

8.  Cholesterol potentiates beta-amyloid-induced toxicity in human neuroblastoma cells: involvement of oxidative stress.

Authors:  Patricia Ferrera; Octavio Mercado-Gómez; Martín Silva-Aguilar; Mahara Valverde; Clorinda Arias
Journal:  Neurochem Res       Date:  2008-02-21       Impact factor: 3.996

9.  Development of classification models for early identification of persons at risk for persistent cognitive decline.

Authors:  T N van den Kommer; H C Comijs; M G Dik; C Jonker; D J H Deeg
Journal:  J Neurol       Date:  2008-07-14       Impact factor: 4.849

10.  Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia.

Authors:  Tiffany F Hughes; Mary Ganguli
Journal:  Curr Psychiatry Rev       Date:  2009-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.